July 20, 2023 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 27, 2023 at 2:30 pm CET (8:30 am ET) to discuss its half year 2023 financial results and provide a second quarter business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
Dial-in numbers:
Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.
Belgium: 32 800 50 201
France: 33 800 943355
Netherlands: 31 20 795 1090
United Kingdom: 44 800 358 0970
United States: 1 888 415 4250
Japan: 81 3 4578 9081
Switzerland: 41 43 210 11 32
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit https://www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:
Erin Murphy
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
Alexandra Roy (US)
This email address is being protected from spambots. You need JavaScript enabled to view it.
Lynn Elton (EU)
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$617.73 |
| Daily Change: | 0.24 0.04 |
| Daily Volume: | 37,966 |
| Market Cap: | US$36.940B |
November 26, 2024 November 20, 2024 November 11, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
